Therapies for Long COVID
Research type
Research Study
Full title
Therapies for Long COVID in non-hospitalised individuals: From symptoms, patient reported outcomes and immunology to targeted therapies (The TLC Study)
IRAS ID
296374
Contact name
Shamil Haroon
Contact email
Sponsor organisation
The University of Birmingham, Birmingham, United Kingdom.
ISRCTN Number
ISRCTN15674970
Duration of Study in the UK
1 years, 8 months, 1 days
Research summary
Background:
Some people who have had COVID-19 develop longer-lasting symptoms, known as Long COVID, despite not being admitted to hospital. Many lack support and are given conflicting advice.Aim:
To work out which treatments are most likely to benefit non-hospitalised people with symptoms associated with Long COVID.Design and methods
Work package 1 will identify people that had COVID-19 but were not hospitalised from GP records. Study participants will be invited to use an app to report Long COVID symptoms, quality of life and work capability.Work package 2 will assess Long COVID symptoms and immune function. Participants with severe symptoms will be contacted by a nurse to provide advice/support. Blood test results and wearable data will help us understand which treatments might be best to support specific groups of Long COVID patients.
Work package 3 will review evidence for treatments for Long COVID including drugs and supportive interventions (e.g. for mental health or tiredness). Working with patients, doctors and other experts, we will recommend treatments that should be tested in Long COVID patients and develop supportive interventions for further evaluation.
Patient and public involvement
People with COVID lived experience have co-designed this research proposal. A lived experience advisory panel will work with us throughout the project and meet regularly to contribute to all aspects of the study.Dissemination
Results will be published, presented at conferences and made available for use by other researchers. We will host a study-specific website and Twitter account and will share lay summaries coproduced with our patient partners.REC name
West Midlands - Solihull Research Ethics Committee
REC reference
21/WM/0203
Date of REC Opinion
13 Oct 2021
REC opinion
Further Information Favourable Opinion